徐放性注射剤市場：用量、投与経路、エンドユーザー別-2025-2030年の世界予測

徐放性注射剤市場の2023年の市場規模は21億5,000万米ドルで、2024年には22億9,000万米ドルに達すると予測され、CAGR 6.95％で成長し、2030年には34億5,000万米ドルに達すると予測されています。

徐放性注射剤は、製薬業界において極めて重要なセグメントであり、長期間にわたって徐々に薬剤を放出する製剤に重点を置き、それによって患者のコンプライアンスと治療成績を向上させています。これらの注射剤は慢性疾患の治療において極めて重要であり、安定した薬物放出により投与頻度を減らし、患者のアドヒアランスを向上させる。主な用途は、腫瘍学、内分泌学、神経学などの治療分野にわたっています。市場は、慢性疾患の有病率の上昇、ドラッグデリバリー技術の進歩、簡便な治療レジメンへの嗜好の高まりによって活性化しています。管理しやすい長期投薬ソリューションを必要とする老年人口が急増していることも大きなチャンスです。革新的な研究は、ドラッグデリバリーシステムの安全性と効率を大幅に向上させることができる、薬剤カプセル化用の生分解性ポリマーの開発に向けられています。しかし、新興国市場は、開発コストの高さや規制要件の厳しさといった制約に直面しており、これが成長の妨げとなっています。さらに、副作用の可能性や製剤の複雑さも課題となっています。こうした課題にもかかわらず、市場にはチャンスがあふれています。企業は、放出制御機構に革命をもたらす可能性のある、新規の生分解性材料とナノテクノロジーの統合に焦点を当てた調査に投資することが推奨されます。学術機関との共同研究は、規制基準への準拠を確保しながらイノベーションを推進する上で実りあるものとなる可能性があります。市場競争はますます激化しており、技術的進歩と市場浸透のために戦略的提携や合併が急増しています。北米は、洗練されたヘルスケア・インフラと研究開発への多額の投資により、依然として圧倒的な強さを誇っています。しかし、アジア太平洋の新興市場は、ヘルスケア制度の改善と先端治療薬への需要の高まりから、未開拓の可能性を秘めています。結論として、徐放性注射剤は、大きな成長の可能性を秘めたダイナミックな市場を体現しており、事業拡大の成功のためには、戦略的イノベーションと規制状況の真摯なナビゲーションを必要としています。

市場力学：急速に進化する徐放性注射剤市場の主要市場インサイトを公開

徐放性注射剤市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 生活習慣の悪化による主要慢性疾患の有病率の増加
  • 小児・老年向け需要の増加徐放性注射剤
  • 注射剤は経口剤よりも生物学的利用能が高い
• 市場抑制要因
  • 充填時のレオロジー変化、長期保存時の不安定性、放出速度の非調整性
• 市場機会
  • ナノテクノロジー、ミクロネーション、安定化プロセスなどの技術の進歩
  • 天然および化学合成の生分解性材料のイントロダクション
• 市場の課題
  • 薬剤費の高騰と熟練専門家の不足

ポーターの5つの力：徐放性注射剤市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：徐放性注射剤市場における外部からの影響の把握

外部マクロ環境要因は、徐放性注射剤市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析徐放性注射剤市場における競合情勢の把握

徐放性注射剤市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス徐放性注射剤市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、徐放性注射剤市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨徐放性注射剤市場における成功への道筋を描く

徐放性注射剤市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 不健康な生活習慣の増加により、主要な慢性疾患の罹患率が上昇している
    • 小児科・老年科の需要増加徐放性注射剤
    • 注射剤は経口剤よりも生物学的利用能が優れている
  • 抑制要因
    • 充填中のレオロジー変化、長期保存時の不安定性、調整不可能な放出速度
  • 機会
    • ナノテクノロジー、ミクロネーション、安定化プロセスなどの技術の進歩
    • 天然および化学合成生分解性材料のイントロダクション
  • 課題
    • 医薬品の高価格と熟練した専門家の不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 徐放性注射剤市場投与量別

• インサイチューフォーミング処方
• インサイチュ形成ゲルシステム
• In situ形成微粒子システム
• リポソーム
• マイクロカプセル
• マイクロスフィア
• 高分子ミセル

第7章 徐放性注射剤市場：投与経路別

• 動脈間
• 心臓内
• 皮内
• 筋肉内
• 静脈内
• 皮下

第8章 徐放性注射剤市場：エンドユーザー別

• 診断検査室
• 病院
• 専門クリニック

第9章 南北アメリカの徐放性注射剤市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の徐放性注射剤市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの徐放性注射剤市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Dr. Reddy's Laboratories
• GP Pharm S.A.
• Innocore Pharmaceuticals
• Janssen Pharmaceutical Companies by Johnson & Johnson
• Novartis AG
• Oakwood Laboratories
• Pacira Pharmaceuticals, Inc.
• PhaseBio Pharmaceuticals, Inc
• Taiwan Liposome Company（TLC）
• ViiV Healthcare
• Xbrane Biopharma AB

LIST OF FIGURES

• FIGURE 1. SUSTAINED RELEASE INJECTABLES MARKET RESEARCH PROCESS
• FIGURE 2. SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SUSTAINED RELEASE INJECTABLES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SUSTAINED RELEASE INJECTABLES MARKET DYNAMICS
• TABLE 7. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING GEL SYSTEM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING MICROPARTICLE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY LIPOSOME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY MICROCAPSULE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY MICROSPHERE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMERIC MICELLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTERARTERIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRACARDIAC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 54. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 57. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 109. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 121. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 124. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 154. SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023

The Sustained Release Injectables Market was valued at USD 2.15 billion in 2023, expected to reach USD 2.29 billion in 2024, and is projected to grow at a CAGR of 6.95%, to USD 3.45 billion by 2030.

Sustained Release Injectables are a pivotal segment within the pharmaceutical industry, focusing on formulations that allow for the gradual release of medication over an extended period, thereby improving patient compliance and therapeutic outcomes. These injectables are crucial in treating chronic conditions, offering a steady drug release that reduces the frequency of administration and enhances patient adherence. Key applications span across therapeutic areas such as oncology, endocrinology, and neurology. The market is fueled by the rising prevalence of chronic diseases, advancements in drug delivery technologies, and a growing preference for convenient treatment regimens. A significant opportunity lies in the burgeoning geriatric population who require manageable long-term medication solutions. Innovative research is directed towards developing biodegradable polymers for drug encapsulation, which can significantly enhance the safety and efficiency of drug delivery systems. However, the market faces limitations such as the high cost of development and stringent regulatory requirements, which can impede growth. Additionally, potential adverse reactions and the complexity of formulation pose challenges. Despite these challenges, the market is rife with opportunities. Companies are recommended to invest in research focused on novel biodegradable materials and Nanotechnology integration, which could revolutionize controlled release mechanisms. Collaborations with academic institutions could prove fruitful in driving innovation while ensuring compliance with regulatory standards. The market is increasingly competitive, fostering a surge in strategic alliances and mergers to leverage technological advancements and market penetration. North America remains a dominant player due to its sophisticated healthcare infrastructure and substantial investment in R&D. However, emerging markets in Asia-Pacific present untapped potential given their improving healthcare systems and growing demand for advanced therapeutics. In conclusion, sustained release injectables embody a dynamic market with significant growth potential, demanding strategic innovation and diligent navigation of regulatory landscapes for successful business expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sustained Release Injectables Market

The Sustained Release Injectables Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of major chronic diseases due to increasing adoption of poor lifestyle habits
  • Rise in demand for paediatric and geriatric sustained release injectables
  • Injectable preparations have a better bioavailability than oral preparations
• Market Restraints
  • Rheological changes during filling, instability on long-term storage and nonadjustable release rate
• Market Opportunities
  • Advancement in technology such as nanotechnology, micronation, and stabilization process
  • Introduction of natural and chemosynthetic biodegradable materials
• Market Challenges
  • High cost of drugs and lack of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Sustained Release Injectables Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sustained Release Injectables Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sustained Release Injectables Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sustained Release Injectables Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sustained Release Injectables Market

A detailed market share analysis in the Sustained Release Injectables Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sustained Release Injectables Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sustained Release Injectables Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sustained Release Injectables Market

A strategic analysis of the Sustained Release Injectables Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sustained Release Injectables Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddy's Laboratories, GP Pharm S.A., Innocore Pharmaceuticals, Janssen Pharmaceutical Companies by Johnson & Johnson, Novartis AG, Oakwood Laboratories, Pacira Pharmaceuticals, Inc., PhaseBio Pharmaceuticals, Inc, Taiwan Liposome Company (TLC), ViiV Healthcare, and Xbrane Biopharma AB.

Market Segmentation & Coverage

This research report categorizes the Sustained Release Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Dosage, market is studied across In Situ Forming Formulations, In Situ Forming Gel System, In Situ Forming Microparticle Systems, Liposome, Microcapsule, Microsphere, and Polymeric Micelles.
• Based on Route of Administration, market is studied across Interarterial, Intracardiac, Intradermal, Intramuscular, Intravenous, and Subcutaneous.
• Based on End-User, market is studied across Diagnostic Laboratories, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of major chronic diseases due to increasing adoption of poor lifestyle habits
    • 5.1.1.2. Rise in demand for paediatric and geriatric sustained release injectables
    • 5.1.1.3. Injectable preparations have a better bioavailability than oral preparations
  • 5.1.2. Restraints
    • 5.1.2.1. Rheological changes during filling, instability on long-term storage and nonadjustable release rate
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancement in technology such as nanotechnology, micronation, and stabilization process
    • 5.1.3.2. Introduction of natural and chemosynthetic biodegradable materials
  • 5.1.4. Challenges
    • 5.1.4.1. High cost of drugs and lack of skilled professionals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Sustained Release Injectables Market, by Dosage

• 6.1. Introduction
• 6.2. In Situ Forming Formulations
• 6.3. In Situ Forming Gel System
• 6.4. In Situ Forming Microparticle Systems
• 6.5. Liposome
• 6.6. Microcapsule
• 6.7. Microsphere
• 6.8. Polymeric Micelles

7. Sustained Release Injectables Market, by Route of Administration

• 7.1. Introduction
• 7.2. Interarterial
• 7.3. Intracardiac
• 7.4. Intradermal
• 7.5. Intramuscular
• 7.6. Intravenous
• 7.7. Subcutaneous

8. Sustained Release Injectables Market, by End-User

• 8.1. Introduction
• 8.2. Diagnostic Laboratories
• 8.3. Hospitals
• 8.4. Specialty Clinics

9. Americas Sustained Release Injectables Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Sustained Release Injectables Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Sustained Release Injectables Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Dr. Reddy's Laboratories
• 2. GP Pharm S.A.
• 3. Innocore Pharmaceuticals
• 4. Janssen Pharmaceutical Companies by Johnson & Johnson
• 5. Novartis AG
• 6. Oakwood Laboratories
• 7. Pacira Pharmaceuticals, Inc.
• 8. PhaseBio Pharmaceuticals, Inc
• 9. Taiwan Liposome Company (TLC)
• 10. ViiV Healthcare
• 11. Xbrane Biopharma AB